MedPath

Evaluation of Growth, Safety, and Efficacy of an Infant Formula for Healthy Term Infants

Not Applicable
Completed
Conditions
Infants
Newborn
Interventions
Other: Study Formula (SF)
Other: Comparator Formula (CF)
Registration Number
NCT04218929
Lead Sponsor
ByHeart
Brief Summary

The purpose of this study is to demonstrate that a new infant formula for term infants supports age-appropriate growth. This study is designed in accordance with Good Clinical Practice guidelines and the requirements of the Code of Federal Regulations, 21CFR106.96. In this randomized, controlled trial (RCT), healthy, term, formula-fed (FF) infants will be randomized to one of two infant formulas: a standard, commercially-available infant formula for term infants (CF) or the study formula for term infants (SF) for 16 weeks. A reference group of human milk-fed infants will also be enrolled. The primary efficacy objective is to compare the growth of infants randomized to the study infant formula (SF) versus growth of infants randomized to the standard commercial infant formula (CF).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
311
Inclusion Criteria
  • Term (no less than 37 weeks, 0 days and less than 42 weeks, 0 days), singleton infant.
  • Birth weight of greater than or equal to 2500 grams.
  • Designated healthy by a physician.
  • Less than or equal to 14 days of age at enrollment.
  • If formula fed, exclusively consuming and tolerating a cow's milk infant formula at enrollment and have a parent who agrees to feed the study formula as a sole source of nutrition for a minimum of 16 weeks.
  • If human milk fed, predominantly consuming and tolerating human milk and have a mother/parent who plans to predominantly feed human milk as sole source of nutrition for a minimum of 16 weeks.
  • Weight for age greater than or equal to 5th percentile and less than or equal to 95th percentile at enrollment.
  • Length for age greater than or equal to 5th percentile and less than or equal to 95th percentile at enrollment.
  • Head circumference for age greater than or equal to 5th percentile and less than or equal to 95th percentile at enrollment.
  • Weight for length greater than or equal to 5th percentile and less than or equal to 95th percentile at enrollment.
  • Not currently receiving and have a parent/guardian who does not plan to give pre- and/or pro-biotics for the full duration of the study.
  • Not currently participating in an interventional clinical trial and have a parent(s) or legal guardian(s) who agree not to enroll the infant in an interventional clinical trial while participating in this trial.
  • Have parent(s) or legal guardian(s) who are capable of completing the written records, questionnaires, and study procedures required by the protocol.
  • Have a parent(s) or legal guardian(s) who have read and voluntarily signed the Institutional Review Board Informed Consent prior to study participation.
Exclusion Criteria
  • Evidence of any anatomic or physiologic condition that would interfere with normal growth, development, or feeding.
  • Infants required to take medications know to influence growth and development.
  • Maternal history with known adverse effects on the fetus and/or the newborn infants.
  • Family history of cow milk protein allergy or soy intolerance/allergy.
  • Infants receiving any amount supplemental human milk with infant formula or visa-versa at time of enrollment.
  • Infants from a multiple birth.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Study Formula (SF)Study Formula (SF)New infant formula for term infants
Comparator Formula (CF)Comparator Formula (CF)Commercially available infant formula for term infants
Primary Outcome Measures
NameTimeMethod
Weight Gain Velocity0 - 16 weeks

G/D

Secondary Outcome Measures
NameTimeMethod
Weight for age Z-scores0 - 16 weeks

Weight for age Z-scores compared to World Health Organization (WHO) growth standards

72-hr record of formula intake at each study visit0 - 16 weeks

OZ/D

Human milk composition (concentrations of proteins, lipids, carbohydrates, vitamins, and minerals3 weeks, 7 weeks

Concentration

Medically-diagnosed adverse events collected throughout the study period0 through 16 weeks

Frequency

Parent report of infant stool frequency at each study visit0 - 16 weeks

Mean

Stool metabolome2 weeks, 16 weeks

Targeted and Untargeted Metabolomics

Blood concentrations of Interleukin-6 (pg/mL), Interleukin-10 (pg/mL), and tumor necrosis factor-alpha (pg/mL)16 weeks

Concentration

Length for age Z-scores0 - 16 weeks

Length for age Z-scores compared to WHO growth standards

Blood concentrations of amino acids (umol/L)16 weeks

Concentration

Weight Measures0 - 16 weeks

KG

Head Circumference Measures0 - 16 weeks

CM

Length Measures0 - 16 weeks

CM

Weight for length Z-scores0 - 16 weeks

Weight for length Z-scores compared to WHO growth standards

Length Gain Velocity0 - 16 weeks

CM/D

Head circumference for age Z-scores0 - 16 weeks

Head circumference for age Z-scores compared to WHO growth standards

Parent rating of infant stool consistency at each study visit0 - 16 weeks

Mean. Quinlan et al Likert scale; 0=no bowel movement, 1=hard \[dry hard pellets\], 2=formed \[definite shape, not dry\], 3=soft \[no definite shape, pasty\], 4=loose \[no shape, some water\], 5=watery \[no shape, mainly water\]).

Parent report of infant disposition (fussiness, crying, gas, spit up, Infant Characteristics Questionnaire) at each study visit0 - 16 weeks

Mean

Stool microbiome2 weeks, 16 weeks

Fecal microbial taxa and community abundance

Trial Locations

Locations (27)

Topaz Clinical Research

🇺🇸

Apopka, Florida, United States

Pediatric Associates of Fairfield, Inc.

🇺🇸

Fairfield, Ohio, United States

Alabama Clinical Therapeutics

🇺🇸

Birmingham, Alabama, United States

Avanza Medical Research

🇺🇸

Pensacola, Florida, United States

Sarkis Clinical Trials

🇺🇸

Gainesville, Florida, United States

DCOL Center for Clinical Research

🇺🇸

Longview, Texas, United States

ACRC Trials Plano Pediatrics

🇺🇸

Plano, Texas, United States

Houston Clinical Research Associates

🇺🇸

Houston, Texas, United States

Watching Over Mothers and Babies

🇺🇸

Tucson, Arizona, United States

San Gabriel Women's Health

🇺🇸

Arcadia, California, United States

Optum

🇺🇸

Colorado Springs, Colorado, United States

Northern California Research

🇺🇸

Sacramento, California, United States

PAS-Research

🇺🇸

Tampa, Florida, United States

Pediatric Associates of Mt. Carmel, Inc

🇺🇸

Cincinnati, Ohio, United States

The Children's Clinic of Jonesboro, P.A.

🇺🇸

Jonesboro, Arkansas, United States

Clinical Research Prime

🇺🇸

Idaho Falls, Idaho, United States

Sierra Clinical Research

🇺🇸

Las Vegas, Nevada, United States

Jackson Clinic North

🇺🇸

Jackson, Tennessee, United States

HMG Primary Care at Sapling Grove

🇺🇸

Bristol, Tennessee, United States

Southern Clinical Research

🇺🇸

Zachary, Louisiana, United States

Applied Research Center of Arkansas

🇺🇸

Little Rock, Arkansas, United States

Coastal Pediatric Research

🇺🇸

Charleston, South Carolina, United States

Tanner Clinic

🇺🇸

Layton, Utah, United States

HMG Pediatrics at Kingsport

🇺🇸

Kingsport, Tennessee, United States

Schear Family Practice

🇺🇸

Dayton, Ohio, United States

Institute of Clinical Research

🇺🇸

Mentor, Ohio, United States

Coastal Pediatric Associates

🇺🇸

Summerville, South Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath